Skip to main content

Esketamine Nasal Spray Beneficial for Treatment-Resistant Depression

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

THURSDAY, Oct. 5, 2023 -- For patients with treatment-resistant depression, esketamine nasal spray is superior to extended-release quetiapine with respect to remission at week 8, according to a study published in the Oct. 5 issue of the New England Journal of Medicine.

Andreas Reif, M.D., from Goethe University Hospital in Frankfurt, Germany, and colleagues conducted an open-label phase 3b randomized, active-controlled trial involving patients with treatment-resistant depression. Participants were randomly assigned to receive flexible doses of esketamine nasal spray (336 patients) or extended-release quetiapine (340 patient) both in combination with a selective serotonin reuptake inhibitor or a serotonin-norepinephrine reuptake inhibitor. The primary end point was remission, defined as a score of 10 or less on the Montgomery-Åsberg Depression Rating Scale (MADRS), at week 8.

The researchers found that more patients in the esketamine group versus the quetiapine group had remission at week 8 (27.1 versus 17.6 percent) and had no relapse through 32 weeks after remission at week 8 (21.7 versus 14.1 percent). The percentage of patients with remission, the percentage with a treatment response, and the change in the MADRS score from baseline favored esketamine over 32 weeks of follow-up.

"These results show the superiority of esketamine nasal spray to extended-release quetiapine with respect to the primary goal of antidepressant treatment in patients with a poor prognosis, in whom treatment goals are rarely met," the authors write.

The study was funded by Janssen, the manufacturer of esketamine nasal spray.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

Read this next

High Social Media Use Tied to Depression in Only Some Teens

TUESDAY, July 2, 2024 -- High social media use is only tied to increased depression in teens who are already vulnerable, according to a study published online June 26 in...

Small Differences in Weight Change With First-Line Antidepressants

MONDAY, July 1, 2024 -- For eight first-line antidepressants, small differences are seen in mean weight change, with the least weight gain with bupropion, according to a study...

Social Anxiety Tied to Later Risk for Suicidal Ideation, Depression

FRIDAY, June 21, 2024 -- Baseline social anxiety symptoms are associated with two-year suicidal ideation and depressive symptoms, according to a study published online June 10...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.